Please login to the form below

Not currently logged in
Email:
Password:

Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair

The Dimension Therapeutics CEO succeeds Dr Stephen Parker, who becomes a non-executive director

Annalisa JenkinsRNA-focused group Silence Therapeutics has appointed Dimension Therapeutics chief executive officer Dr Annalisa Jenkins as the non-executive chair of its board of directors.

She succeeds Dr Stephen Parker, the company’s non-executive chairman since September 2015, who becomes a non-executive director.

She said: “Silence's technology and IP represent a significant opportunity in the next generation of drugs that will potentially transform the treatment of serious diseases with significant unmet medical need, specifically where the liver is the primary target organ.

“These disorders often have devastating outcomes for patients and their families, and I look forward to contributing to the company’s advancement of these promising product candidates towards the clinic.”

Dr Jenkins brings over 25 years of global industry experience to Silence’s board, with expertise in scientific research, clinical development, regulatory approval and healthcare systems.

Prior to Dimension, Dr Jenkins held multiple leadership positions, including executive vice president, head of global research and development for Merck Serono and senior vice president, head of global medical affairs for Bristol Myers Squibb.

Ali Mortazavi, chief executive officer, Silence Therapeutics, said: “Annalisa’s extensive and broad experience in all aspects of biotechnology, drug development and commercialisation will prove to be invaluable.

“It is a testament to the progress made at Silence that we have been able to attract Annalisa to our Board.”

Dr Jenkins is also a committee member of the science board to the US Food and Drug Administration (FDA) and serves on the advisory board of its Center for Talent Innovation (UK).

25th October 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....